User: Guest  Login
Less Searchfields
Simple search
Title:

ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis.

Document type:
Article
Author(s):
Lingor, Paul; Weber, Markus; Catnu, William; Friede, Tim; Hilgers, Reinhard; Leha, Andreas; Neuwirth, Christoph; Guenther, René; Benatar, Michael; Kuzma-Kozakiewicz, Magdalena; Bidner, Helen; Blankenstein, Christiane; Frontini, Roberto; Ludolph, Albert; Koch, Jan C.
Abstract:
Objectives: Disease-modifying therapies for amyotrophic lateral sclerosis (ALS) are still not satisfactory. The Rho kinase (ROCK) inhibitor fasudil has demonstrated beneficial effects in cell culture and animal models of ALS. For many years, fasudil has been approved in Japan for the treatment of vasospasm in patients with subarachnoid hemorrhage with a favorable safety profile. Here we describe a clinical trial protocol to repurpose fasudil as a disease-modifying therapy for ALS patients. Metho...     »
Journal title abbreviation:
Front Neurol
Year:
2019
Journal volume:
10
Fulltext / DOI:
doi:10.3389/fneur.2019.00293
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/30972018
Print-ISSN:
1664-2295
TUM Institution:
303; Kliniken und Institute; Neurologische Klinik und Poliklinik
 BibTeX